focus -WSS

focus

author：entertainment 2025-09-30 00:47:05 - browse：18324

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： New details revealed about Purdue's marketing of OxyContin

leisure time

WSS

Eye stem cell transplant could help restore vision in injured people

Synthetic human embryos? Researchers say term is overblown

Belarusian journalist sentenced to 4 years in prison as crackdown continues

Why do we get seasonal allergies?

Listen: Racing for gene therapy & a pioneering approval

Brazil's Jair Bolsonaro is barred from running for office until 2030

explore

focus

entertainment

Guidelines to prevent youth baseball injuries need more muscle

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medical experts exlpore how to eliminate bias in clinical algorithms

The high cost of giving birth even with insurance

The pain doctors face in trying to build their families

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA approves first treatment for ultra

Continuity nursing helped my family in our darkest PICU moments

Brazil's Jair Bolsonaro is barred from running for office until 2030

knowledge

FDA approves first treatment for ultra

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Medical experts exlpore how to eliminate bias in clinical algorithms

FDA approves first treatment for ultra

Why do we get seasonal allergies?

Cancer drug shortages' outsize impact on ovarian cancer patients

leisure time

knowledge

hotspot

explore